Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?
- PMID: 29440189
- DOI: 10.1158/1078-0432.CCR-18-0183
Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?
Abstract
Establishing trial-level surrogacy of an intermediate endpoint for predicting survival benefit in future trials is extremely challenging because of the extrapolations required, but there are other useful drug development and patient management applications of intermediate endpoints. Clin Cancer Res; 24(10); 2239-40. ©2018 AACRSee related article by Mushti et al., p. 2268.
©2018 American Association for Cancer Research.
Comment on
-
Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.Clin Cancer Res. 2018 May 15;24(10):2268-2275. doi: 10.1158/1078-0432.CCR-17-1902. Epub 2018 Jan 11. Clin Cancer Res. 2018. PMID: 29326281
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
